# Minnesota — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

For Minnesota, generic/biosimilar trigger is 50% over the previous 12 months; statute is S.F. 2995, verified against its source on 2026-08-14.

- **State:** Minnesota _(verified: appears in the quote below)_
- **Generic/biosimilar trigger:** 50% over the previous 12 months _(verified: appears in the quote below)_
- **Statute:** S.F. 2995 _(verified: appears in the quote below)_

## What the source says

> Minnesota : <https://www.revisor.mn.gov/bills/text.php?version=latest&number=SF2995&session=ls93&session_year=&session_number=0> S.F. 2995 amends the state&rsquo;s Prescription Drug Price Transparency Act to include some technical fixes and clarifications, such as explicitly including &ldquo;biosimilars&rdquo; along with generic drugs in the provision that triggers reporting when there is a WAC increase of at least 50% over the previous 12 months.

## Source

- https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws

Last verified: 2026-08-14. Review by: 2027-02-10.
Part of [State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers](https://referencesource.org/drug-price-transparency-thresholds/).